Expanding the market share of core products in the priority obstetrics and gynecology field
First written in FY2016-Q3. 18 of 31 entries say "Restated". Latest entry: 2026-08-06.
3 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「Women’s healthcare performed steadily, led mainly by Alissa combination tablets, a new dysmenorrhea treatment launched in December 2024, Femeno capsules 100 mg and Favoir tablets.」
In the women’s healthcare area, the Company commenced sales of Alissa combination tablets, a new dysmenorrhea treatment, in December 2024 and states that sales grew as it became a core product. - FY2024-Q2AdvancedAnnual report
「Sales for the second quarter cumulative period increased steadily for core women’s healthcare products, principally Femeno capsules 100 mg and Doxil injection 20 mg, as well as Iopamidol injection, a nonionic urographic and angiographic contrast medium. As a result, sales for the second quarter cumulative period were ¥21,388 million, up 11.2% year on year, and sales for the second quarter cumulative period were ¥21,388 million, up 11.2% year on year.」
Identifies Femeno capsules and Doxil injection as core women’s healthcare products and cites sales of ¥21,388 million, up 11.2% year on year, as evidence of expanded sales. - FY2024-Q1RaisedAnnual report
「In women’s healthcare new drugs, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms; Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology; and Doxil injection 20 mg, an antineoplastic agent. For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets; and Labellefille tablets, both oral contraceptives.」
In addition to its existing women’s healthcare and gynecological products, the Company has identified Doxil injection 20 mg, an antineoplastic agent, as a priority sales product, broadening the scope of its priority products. - FY2023-Q3RestatedAnnual report
「In the women’s healthcare area, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment. For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets; and Labellefille tablets, both oral contraceptives.」
In the women’s healthcare area, the Company continues to focus on sales of Femeno and Utrogestan and expand the market share of multiple gynecological generic products. - FY2023-Q2RestatedAnnual report
「In the women’s healthcare area, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment. For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets; and Labellefille tablets, both oral contraceptives.」
The Company continues to focus on sales of Femeno, Utrogestan and multiple gynecological generic products and expand their market share. - FY2023-Q1RestatedAnnual report
「In the women’s healthcare area, we are focusing on sales of Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment. For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets; and Labellefille tablets, both oral contraceptives.」
In the women’s healthcare area, the Company continues to focus on sales of Femeno and Utrogestan and expand the market share of multiple gynecological generic products. - FY2022RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
The Company continues to focus on sales of Utrogestan and expand the market share of multiple generic products in the obstetrics and gynecology area. - FY2022-Q3RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
The Company continues to focus on sales of Utrogestan and expand the market share of Dienogest tablets, Levonorgestrel tablets, Favoir tablets and Labellefille tablets. - FY2022-Q2AdvancedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology and listed in the National Health Insurance drug price list in April 2022 as a drug used in infertility treatment, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
States that Utrogestan vaginal capsules 200 mg were listed in the National Health Insurance drug price list in April 2022 as a drug for infertility treatment, broadening the sales base in the priority obstetrics and gynecology area. - FY2022-Q1AdvancedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms, and commenced sales in November 2021.」
Describes the specific progress in the obstetrics and gynecology and women’s healthcare areas, namely the commencement of sales of Femeno capsules 100 mg in November 2021 following approval. - FY2021AdvancedAnnual report
「On 27 September 2021, we obtained Japan’s first manufacturing and marketing approval for Femeno capsules 100 mg, a natural progesterone product indicated for suppressing the onset of endometrial hyperplasia when estrogen is administered for menopausal disorders and ovarian loss symptoms.」
Describes the specific product rollout in the obstetrics and gynecology and women’s healthcare areas, namely obtaining domestic manufacturing and marketing approval for Femeno capsules 100 mg. - FY2021-Q3RestatedAnnual report
「For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
In the obstetrics and gynecology area, the Company continues to expand the market share of Dienogest tablets, Levonorgestrel tablets, Favoir tablets and Labellefille tablets. - FY2021-Q2RestatedAnnual report
「For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
In the obstetrics and gynecology area, the Company continues to expand the market share of Dienogest tablets, Levonorgestrel tablets, Favoir tablets and Labellefille tablets. - FY2021-Q1RestatedAnnual report
「For generic products, we are seeking to expand the market share of Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
With obstetrics and gynecology as a priority area, the Company continues to expand the market share of Dienogest tablets, Levonorgestrel tablets, Favoir tablets and Labellefille tablets. - FY2020RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis; Levonorgestrel tablets, an emergency contraceptive; Favoir tablets, an oral contraceptive; and Labellefille tablets, an oral contraceptive.」
With obstetrics and gynecology as a priority area, the Company identifies Favoir tablets and Labellefille tablets, in addition to Utrogestan, Dienogest tablets and Levonorgestrel tablets, as targets for market-share expansion. - FY2020-Q3RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis, and Levonorgestrel tablets, an emergency contraceptive.」
With obstetrics and gynecology as a priority area, the Company continues to focus on sales and expand market share, principally for Utrogestan, Dienogest tablets and Levonorgestrel tablets. - FY2020-Q2RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016, while seeking to expand the market share of generic products, principally Dienogest tablets, a treatment for endometriosis, and Levonorgestrel tablets, an emergency contraceptive.」
With obstetrics and gynecology as a priority area, the Company continues to focus on sales and expand market share, principally for Utrogestan, Dienogest tablets and Levonorgestrel tablets. - FY2019-Q3RestatedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of Utrogestan vaginal capsules 200 mg, a natural progesterone product indicated for luteal-phase support in assisted reproductive technology, for which we obtained our first manufacturing and marketing approval in 2016, while seeking to expand the market share of core products, including Dienogest tablets, a generic treatment for endometriosis, and Lunabell combination tablets ULD, a new dysmenorrhea treatment. In March 2019, we also commenced sales of Levonorgestrel tablets, a generic emergency contraceptive.」
In the obstetrics and gynecology area, the Company continues to expand the market share of core products including Utrogestan, Dienogest tablets and Lunabell combination tablets ULD, and restates the commencement of sales of Levonorgestrel tablets in March 2019. - FY2019-Q2AdvancedAnnual report
「In March 2019, we commenced sales of Levonorgestrel tablets, a generic emergency contraceptive. Going forward, we will continue to contribute to improving the quality of life of more patients by expanding our product portfolio in obstetrics and gynecology.」
In the priority obstetrics and gynecology area, the Company commenced sales of Levonorgestrel tablets, an emergency contraceptive, in March 2019 and expanded its product portfolio. - FY2019-Q1RestatedAnnual report
「We are seeking to expand the market share of core products, including Dienogest tablets, a generic treatment for endometriosis, and Lunabell combination tablets ULD, a new dysmenorrhea treatment.」
The Company continues to expand the market share of core products in the obstetrics and gynecology area, including Dienogest tablets and Lunabell combination tablets ULD. - FY2018-Q3AdvancedAnnual report
「In June 2018, we launched Dienogest orally disintegrating tablets, our first orally disintegrating tablet and a generic treatment for endometriosis, and expect it to make a further contribution to the treatment of endometriosis.」
Describes the specific product rollout in the priority obstetrics and gynecology area, namely the launch of the Company’s first orally disintegrating tablet, Dienogest orally disintegrating tablets, in June 2018. - FY2018-Q2RestatedAnnual report
「We are seeking to expand the market share of core products, including Dienogest tablets, a generic treatment for endometriosis launched in June 2017, and Lunabell combination tablets ULD, a new dysmenorrhea treatment.」
The Company continues to expand the market share of core products in the obstetrics and gynecology area, including Dienogest tablets and Lunabell combination tablets ULD. - FY2018-Q1RestatedAnnual report
「We are seeking to expand the market share of core products, including Dienogest tablets, a generic treatment for endometriosis launched in June 2017, and Lunabell combination tablets ULD, a new dysmenorrhea treatment.」
Following the launch of Dienogest tablets, the Company continues to expand the market share of core products in the obstetrics and gynecology area. - FY2017AdvancedAnnual report
「In June 2017, we launched Dienogest tablets, a generic treatment for endometriosis. In addition to Lunabell combination tablets ULD, a new dysmenorrhea treatment, we are broadening treatment options for endometriosis and continuing to expand the market share of core products, particularly infertility treatments.」
In the priority obstetrics and gynecology area, the Company launched a new endometriosis treatment and advanced the expansion of treatment options and the market share of core products. - FY2017-Q3RestatedAnnual report
「We are seeking to expand sales of Lunabell combination tablets ULD, a dysmenorrhea treatment, and the market share of core products, including infertility treatments.」
In the priority obstetrics and gynecology area, we continue to expand sales of Lunabell combination tablets ULD and the market share of core products. - FY2017-Q2RestatedAnnual report
「We are seeking to expand sales of Lunabell combination tablets ULD, a dysmenorrhea treatment, and the market share of core products, including infertility treatments.」
In the priority obstetrics and gynecology area, we continue to expand sales of Lunabell combination tablets ULD and the market share of core products. - FY2017-Q1RestatedAnnual report
「We are seeking to expand sales of Lunabell combination tablets ULD, a dysmenorrhea treatment, and the market share of core products, including infertility treatments.」
In the priority obstetrics and gynecology area, we continue to expand sales of Lunabell combination tablets ULD and the market share of core products. - FY2016-Q3First statedAnnual report
「In the priority obstetrics and gynecology area, we are focusing on sales of the new dysmenorrhea treatment Lunabell combination tablets ULD and seeking to expand the market share of core products, including infertility treatments.」
Identifies obstetrics and gynecology as a priority area and describes efforts to focus on sales of specific products and expand market share.